Michael Voronkov

Dr. Michael Voronkov

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
GBGustavo Basurto-Islas
Gustavo Basurto-Islas
JBJulie Blanchard
Julie Blanchard
YTYunn Chyn Tung
Yunn Chyn Tung
JFJosé R. Fernández
José R. Fernández
MVMichael Voronkov
Michael Voronkov
Khalid IqbalKhalid Iqbal
Khalid Iqbal

1 January 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MVMichael Voronkov
Michael Voronkov
GNGeorgiy Nikonov
Georgiy Nikonov
JAJanna Ataiants
Janna Ataiants
LILevon Isakulyan
Levon Isakulyan
CSCristina Stefanut
Cristina Stefanut
JAJohn Abernethy
John Abernethy

1 February 2021 in Neurochemistry International
Verified
Journal Article
Closed access
MVMichael Voronkov
Michael Voronkov
BCBenjamin Cocchiaro
Benjamin Cocchiaro
JSJeffry B. Stock
Jeffry B. Stock

2 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MCMihai Cernea
Mihai Cernea
GNGeorge Nikonov
George Nikonov
JAJanna Ataiants
Janna Ataiants
LSLaura-Cristina Stefanut
Laura-Cristina Stefanut
JAJohn Abernethy
John Abernethy
MVMichael Voronkov
Michael Voronkov
Developing an effective antidote for fentanyl-induced overdose to achieve timely reversal is an unmet public health need. Previously, we found that naloxone derivative NX90 with mild κ-opioid agonistic properties was three-fold more effective than the parent naloxone in reversing a fentanyl overdose in rats. To investigate whether κ-agonistic properties could indeed augment the robustness of overdose reversal, we evaluated a κ-agonist/µ-antagonist nalbuphine (NB) as well as its combinations with naloxone (NX) in a fentanyl overdose model in rodents. An administration of either NB or NX as single agents at 0.1 mg/kg doses produced a full recovery in 90 ± 9.9 min and 11.4 ± 2.7 min, respectively. A higher dose of NX at 0.2 mg/kg reversed an overdose within 4.8 ± 1.0 min. In contrast to that, the coadministration of NB and NX at 0.1 mg/kg each produced a synergistic effect, with overdose reversal in 3.4 ± 0.2 min. The coadministration of NX and NB at sub-therapeutic doses of 0.05 mg/kg each was also 1.2-fold more effective than NX at 0.2 mg/kg. We further found that co-administration of NB at different doses (0.025, 0.05, 0.1 mg/kg) and ratios (1:4 and 1:1) with NX had differential effects on overdose reversal, cardiorespiratory liabilities, and analgesia.

11 May 2006 in Tetrahedron Letters
Verified
Journal Article
Closed access
MVMichael Voronkov
Michael Voronkov
KGKunjian Gu
Kunjian Gu
SBSimon D.P. Baugh
Simon D.P. Baugh
MBMichael R. Becker
Michael R. Becker

Verified
Journal Article
Open access
PDF file
YKYuki Kikuchi
Yuki Kikuchi
ESEriko Sugano
Eriko Sugano
SYShiori Yuki
Shiori Yuki
KTKitako Tabata
Kitako Tabata
YEYuka Endo
Yuka Endo
Hiroshi TomitaHiroshi Tomita
Hiroshi Tomita
Age-related macular degeneration is a progressive retinal disease that is associated with factors such as oxidative stress and inflammation. In this study, we evaluated the protective effects of SIG-1451, a non-steroidal anti-inflammatory compound developed for treating atopic dermatitis and known to inhibit Toll-like receptor 4, in light-induced photoreceptor degeneration. SIG-1451 was intraperitoneally injected into rats once per day before exposure to 1000 lx light for 24 h; one day later, optical coherence tomography showed a decrease in retinal thickness, and electroretinogram (ERG) amplitude was also found to have decreased 3 d after light exposure. Moreover, SIG-1451 partially protected against this decrease in retinal thickness and increase in ERG amplitude. One day after light exposure, upregulation of inflammatory response-related genes was observed, and SIG-1451 was found to inhibit this upregulation. Iba-1, a microglial marker, was suppressed in SIG-1451-injected rats. To investigate the molecular mechanism underlying these effects, we used lipopolysaccharide (LPS)-stimulated rat immortalised Müller cells. The upregulation of C-C motif chemokine 2 by LPS stimulation was significantly inhibited by SIG-1451 treatment, and Western blot analysis revealed a decrease in phosphorylated I-κB levels. These results indicate that SIG-1451 indirectly protects photoreceptor cells by attenuating light damage progression, by affecting the inflammatory responses.